PP
BHVN

PDT Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

PDT Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-46,057
Closed -$1.7M – 547
2018
Q4 		$1.7M Buy
46,057
+9,527
+26% +$343K 0.1% 223
2018
Q3 		$1.37M Sell
36,530
-35,670
-49% -$1.31M 0.06% 275
2018
Q2 		$2.85M Sell
72,200
-36,739
-34% -$1.17M 0.11% 215
2018
Q1 		$2.81M Buy
108,939
+13,117
+14% +$392K 0.09% 229
2017
Q4 		$2.58M Buy
+95,822
New +$2.64M 0.08% 267

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PDT Partners's BHVN Position: Q1 2019 in Review

PDT Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2019, closing a stake of 46,057 shares — an estimated $1.7M sold.

PDT Partners first reported a position in BHVN in Q4 2017 and held it in 5 quarters. The position peaked at $2.85M in Q2 2018. 170 funds tracked by Wall St. Rank hold BHVN as of Q1 2019.

  • PDT Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2019 after selling out during the quarter.
  • PDT Partners sold 46,057 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2019, an estimated $1.7M.
  • PDT Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 5 quarters.
  • PDT Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.85M in Q2 2018.
  • 170 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2019.

Based on PDT Partners's 13F filing for Q1 2019, filed 15 May 2019.